WO2005094783A2 - Serum-stable amphoteric liposomes - Google Patents
Serum-stable amphoteric liposomes Download PDFInfo
- Publication number
- WO2005094783A2 WO2005094783A2 PCT/DE2005/000589 DE2005000589W WO2005094783A2 WO 2005094783 A2 WO2005094783 A2 WO 2005094783A2 DE 2005000589 W DE2005000589 W DE 2005000589W WO 2005094783 A2 WO2005094783 A2 WO 2005094783A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposomal
- formulation according
- chol
- molar composition
- membrane
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims description 74
- 239000000203 mixture Substances 0.000 claims abstract description 120
- 238000009472 formulation Methods 0.000 claims abstract description 70
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000012528 membrane Substances 0.000 claims description 47
- 150000002632 lipids Chemical class 0.000 claims description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 22
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 16
- 235000012000 cholesterol Nutrition 0.000 claims description 15
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 15
- 125000002091 cationic group Chemical group 0.000 claims description 13
- 125000000129 anionic group Chemical group 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 108091023037 Aptamer Proteins 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 6
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 claims 1
- 108091027076 Spiegelmer Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 34
- 230000003834 intracellular effect Effects 0.000 abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 14
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- -1 Spiegelmers Proteins 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 8
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 8
- 229960004502 levodopa Drugs 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 3
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005188 flotation Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 2
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 2
- FJUOBOJIJWDANZ-UHFFFAOYSA-N 2-[(4-anilinophenyl)iminomethyl]-5-(diethylamino)phenol Chemical compound CCN(CC)C1=CC(=C(C=C1)C=NC2=CC=C(C=C2)NC3=CC=CC=C3)O FJUOBOJIJWDANZ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000435574 Popa Species 0.000 description 2
- 241001441550 Zeiformes Species 0.000 description 2
- AMWRMNZJUUZXJU-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbamate Chemical compound C1C=C2C[C@@H](OC(N)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 AMWRMNZJUUZXJU-JDTILAPWSA-N 0.000 description 2
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002800 charge carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 2
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007762 localization of cell Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- LNXLHAWHHNDIDC-QFIPXVFZSA-N (2s)-2-[3-(hexadecanoylamino)propanoylamino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 LNXLHAWHHNDIDC-QFIPXVFZSA-N 0.000 description 1
- WKJDWDLHIOUPPL-JSOSNVBQSA-N (2s)-2-amino-3-({[(2r)-2,3-bis(tetradecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCC WKJDWDLHIOUPPL-JSOSNVBQSA-N 0.000 description 1
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 1
- FXAOZKICNGZUNY-ZVDJXTMWSA-M 1,2-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOC(C)C([N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC FXAOZKICNGZUNY-ZVDJXTMWSA-M 0.000 description 1
- SEJIZBLNTAYKNX-UHFFFAOYSA-N 1,2-di(hexadecanoyloxy)propyl-trimethylazanium Chemical class CCCCCCCCCCCCCCCC(=O)OC(C)C([N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC SEJIZBLNTAYKNX-UHFFFAOYSA-N 0.000 description 1
- LDLXELFZFTYLQG-UHFFFAOYSA-N 1,2-di(tetradecanoyloxy)propyl-trimethylazanium Chemical class CCCCCCCCCCCCCC(=O)OC(C)C([N+](C)(C)C)OC(=O)CCCCCCCCCCCCC LDLXELFZFTYLQG-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- BSTPEQSVYGELTA-UHFFFAOYSA-N 2-(dimethylamino)ethanol;hydrobromide Chemical compound [Br-].C[NH+](C)CCO BSTPEQSVYGELTA-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- LUTRZKIJGBTTPE-UHFFFAOYSA-N morpholin-4-yloxyphosphonamidic acid Chemical compound NP(O)(=O)ON1CCOCC1 LUTRZKIJGBTTPE-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- OIWCYIUQAVBPGV-DAQGAKHBSA-N {1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}serine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OIWCYIUQAVBPGV-DAQGAKHBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Definitions
- the invention relates to amphoteric liposomal formulations which show particular serum stability and are suitable for the intracellular delivery of oligonucleotides.
- RNA short interfering ribonucleic acids
- Another approach is to use a carrier that protects the siRNA from attack by enzymes and can transport it to the site of action.
- Liposomes have been used as pharmaceutical carriers for drugs for some time.
- Vdrformed liposomes and nucleic acids are also produced for the above-mentioned applications.
- the complex formation or the mostly not stable in serum Liposomal formulations mean that the stability of the oligonucleotides is not guaranteed over a long period of time.
- Amphoteric liposomes are a new class of liposomes that offer advantageous properties over conventional liposomes and purely cationic systems for intracellular delivery. Negatively charged active ingredients, such as the Nucleic acids can be effectively packed inside these liposomes, although the total charge of the liposomes remains negative at physiological pH. By changing the ambient pH, as occurs in the endosomal uptake of liposomes in cells, from neutral to slightly acidic, the charge of the amphoteric liposomes also changes from anionic to slightly cationic and the advantages of a cationic transfection reagent are exploited. These liposomes are described for the first time in WO 02/66012 A2. WO 02/66490 and WO 02/66489 (WO 03/070220 and WO 03/070735) present pH-sensitive lipids which are suitable for the construction of amphoteric liposomes.
- amphoteric liposomes which enclose small oligonucleotides, such as siRNA and / or antisense molecules, in their interior and do not or only release a small part under serum conditions and are therefore suitable for parenteral administration ,
- the invention solves the problem comprehensively by providing liposomal formulations with an aqueous interior
- amphoteric lipids with a proportion of 5-30 mol%, or mixtures of cationic and anionic lipids with a total proportion of at most 50 mol%, the formulation as an active ingredient in the aqueous interior comprising at least one oligonucleotide.
- the oligonucleotides relevant for this embodiment of the invention are composed of 5-100, preferably 5-40 and particularly preferably 10-25 nucleotides or base pairs.
- the oligonucleotides can be present as a single strand (e.g. antisense oligonucleotides), as a double strand (e.g. small-interfering RNA, decoy-oligonucleotides) or in complex folds (e.g. aptamers, Spiegelmers, ribozymes).
- oligonucleotides relevant to this invention are made up of deoxyribonucleotides or ribonucleotides and their chemically modified derivatives, such as phosphorothioate DNA (PS), 2'-O-methyl RNA (OMe), 2'-O-methoxy-ethyl RNA (MOE) , Peptide nucleic acid (PNA), N3'-P5 'Phosphoroamidate (NP), 2'-fluoro-arabino nucleic acid (FANA), Locked nucleic acid (LNA), Morpholino phosphoroamidate (MF), Cyclohexene nucleic acid (CeNA), Tricyclo-DNA (tcDNA)).
- PS phosphorothioate DNA
- OMe 2'-O-methyl RNA
- MOE 2'-O-methoxy-ethyl RNA
- PNA Peptide nucleic acid
- NP N3'-P5 'Phosphor
- aptamers or Spiegelmers are included in the liposomes.
- Aptamers are DNA or RNA-based oligonucleotides with a complex three-dimensional structure. Due to this structure, aptamers can bind to protein targets in a very specific and highly affine manner and thus have a therapeutic, usually extracellular, effect. Their functionality is almost identical to that of monoclonal antibodies.
- Spiegelmers are made up of L-ribose and L-2'-deoxyribose units. Just like aptamers, these mirror-image nucleic acids bind specifically to protein targets. Due to the chiral inversion, Spiegelmers, in contrast to conventional D-oligonucleotides, have increased stability against enzymatic degradation.
- the basic structure of the amphoteric liposomes according to the invention is formed by neutral framework lipids which have a membrane share of 5 to 65 mol%, preferably 10 to 60 mol%.
- Suitable lipids are phosphatidylcholines, such as DMPC, DPPC, DSPC, DOPC and POPC, which can be of synthetic as well as natural or semi-synthetic origin.
- the liposomes according to the invention preferably have a content of 30 to 50 mol%, preferably 35 to 45 mol%, of cholesterol in the membrane.
- lipids that can be used as charge carriers for amphoteric liposomes are derived from the basic chemical structure of cholesterol (for example the compounds disclosed in WO 02/66490 and WO 02/6648). Surprisingly, it was found that these cholesterol derivatives in general, especially MoChol, HisChol, Chems, HistChol, do not have the stabilizing effect of native cholesterol, so it is advantageous if the sum of all sterol-based lipids does not exceed 60 mol%.
- amphoteric charge behavior can be formed in two ways: by using amphoteric lipids or by suitable mixtures of pH-sensitive cationic and anionic lipids, as are disclosed in WO 02/066012. If amphoteric lipids are used, the membrane part is between 5 and 30 mol%, more preferably between 5 and 20 mol%, in the case of mixtures the total charge carrier fraction is preferably not more than 50 mol%, more preferably between 15 and 45 mol%. In a preferred embodiment of the invention, amphoteric formulations are composed as follows:
- - Cholesterol with 35 - 45 mo_% - amphoteric lipid, selected from the group HistChol, HistDG, isoHistSuccDG, Acylcamosin, HCChol with 5 - 20 mol%.
- formulations are composed as follows: base lipid selected from the group DMPC, DPPC, DSPC with 10 to 50 mol%
- cationic and anionic lipids of which at least one is pH-sensitive, selected from groups a) cationic: DMTAP, DPTAP, DOTAP, DC-Chol, MoChol, HisChol, DPIM, CHIM, DORIE, DDAB, DAC-Chol, TC- Chol, DOTMA, DOGS, C (18) 2Gly + N, N-dioctadecylamidoglycin, CTAP, CpyC, DODAP, and DOEPC with 5 to 40 mol%.
- the formulation and its composition are selected from Table 3.
- formulations according to the invention for use of the formulations according to the invention as a pharmaceutical carrier, it may be expedient to add substances which increase the shelf life and which serve to regulate the osmotic pressure.
- the liposomes according to the invention can be produced by methods according to the prior art, such as, for example, extrusion through membranes of defined pore size, ethanol injection or high-pressure homogenization. Exemplary designs are given in the examples.
- Active substance not included is separated off. Suitable separation processes are used for this, so that at least 90% of the active substance is enclosed in the liposome and less than 10% of the active substance is outside the liposome. Chromatographic methods, centrifugation, dialysis or ultrafiltration can be used for this.
- the liposomal formulations according to the invention can be used for the therapeutic treatment of a mammal. They can also be used for the therapeutic treatment of people.
- the liposomal formulations according to the invention are particularly suitable for parenteral administration, preferably for intravenous administration.
- the invention accordingly also relates to a kit which optionally comprises the liposomal formulation according to the invention together with a suitable carrier, and to the use of the kit in diagnosis and therapy.
- DOTMA 1-dioIeyloxypropyl) -N, N, N-trimethylammonium chloride
- DOTAP (1,2-dioleoyloxypropyl) -N, N, N-trimethylammonium salt
- HistChol N-histidinyl cholesterol hemisuccinate HistChol N-histidinyl cholesterol hemisuccinate.
- IsoHistSuccDG 1, 2 Dipalmitoylglycerol-O ⁇ -histidinyl-N ⁇ -hemisuccinate, & Distearoyl-, Dimyristoyl, Dioleoyl or palmitoyl-oleoyl derivatives
- Figure 2 Assignment of a 96-well microtiter plate for the serum stability test, the release of the fluorescent marker CF is measured
- Figure 3 Fluorescence microscope image next to a phase contrast image for cell localization.
- a mixture of the lipids named in Table 1 is dissolved in the molar ratios given in chloroform and then completely dried in a rotary evaporator in vacuo.
- the lipid film is mixed with 10 mM Hepes, 150 mM NaCl, pH 7.5 that a 100 mM
- the liposomes are repeatedly passed through a membrane with a
- Pore width of 400 nm extruded is 400 nm extruded.
- Lipid film uses a solution of the dye, after: 500 mg CF in 130 ul 5
- the CF which is not included, is separated off by gel filtration.
- a lipid mixture of the following composition DMPC / MoChol / DG-Succ / Chol 40: 10: 10: 40 (mol%) is dissolved in chloroform at 50 ° C. and then completely dried in a rotary evaporator in vacuo.
- the liposomes are extruded several times through a membrane with a pore size of 200 nm or 400 nm (Avestin LiposoFast, polycarbonate membrane with a pore size of 200 or 400 nm).
- a pH of 7.5 is adjusted by adding a 1 mol / L HEPES stock solution.
- the fraction of the enclosed Cy5.5-anti-CD40-ODN (antisense oligonucleotide) is determined after separation of the freely available active ingredient by sedimentation three times in the ultracentrifuge at 60,000 x g for 45 min using fluorescence spectroscopy.
- the inclusion efficiency of the oligonucleotide is seen by determining the lipid content and the fluorimetric Cy5.5 determination in relation to the material use of lipid and ODN and is 53% for the formulation.
- Carboxyflourescein (CF) is used as a model drug, which like oligonucleotides is negatively charged at physiological pH.
- the serum stability of the CF-filled liposomes is observed over a period of 24 h at 37 ° C.
- the release of the CF from the liposomes is observed over time by fluorescence measurement.
- Liposome formulations can be tested per 96-well plate. To determine the percentage of CF released, the sample incubated in buffer is measured both directly (base value) and after opening the liposomes by adding Triton (Triton value or 100% value).
- Sterile-filtered serum and 1 mM liposomes are combined in a total volume of 500 ⁇ l.
- the same approach is prepared as a control with buffer instead of serum.
- a 96-well plate is prepared as follows before the respective sampling: In the wells of a row, columns 1, 3, 5, 7, 9 and 11, 5 ⁇ l buffer (10 mM Hepes, 150 mM NaCl, pH 7.5 ) submitted. In columns 2, 4, 6, 8, 10 and 12 each 5 ⁇ l 10% Triton X-100.
- the 96-well plate is loaded as shown in Figure 2.
- Columns 1-6 each contain 5 ⁇ l of the liposomes incubated in buffer, columns 7-12 each in serum incubated.
- 290 ⁇ l buffer are added to the 5 ⁇ l sample plus 5 ⁇ l buffer or Triton.
- a base and a triton value are used again.
- the times are as follows: zero, zero, 15 minutes, 30 minutes, 1 hour, 3 hours, 5 hours, 24 hours.
- a plate reader with 485/530 nm filters is used to measure the fluorescence.
- the relative release values are calculated from the measured fluorescence data, in that the triton value corresponds to 100% release.
- Table 1 shows a number of formulations tested. It can be seen that only compositions according to the invention have a high serum stability.
- the antisense oligonucleotide (ODN) used is an 18-th phosphorothioate with a FITC label at the 5 'end (fluorescein isothiocyanate).
- ODN antisense oligonucleotide
- Liposomes with FITC-ODN were prepared: 0.5 ml of a 1 mM lipid solution with 9 ⁇ g ODN.
- the liposomes were floated in a discontinuous sucrose gradient with 0, 0.8 and 1, 2 M sucrose in Hep 10 , NaCI 150 (10mM Hepes, 150mM NaCI).
- siRNA anti GFP
- amphoteric liposomes 5: 1 to 10: 1 is chosen as the charge ratio of cationic lipid to anionic siRNA.
- the siRNA in 10mM Hepes, 10mM NaCl pH 7.2
- the hydration buffer (10mM NaAcetate, 10mM NaCl, 280mM sucrose, pH 4.5) and applied to the lipid film so that a 5-10 mM lipid suspension is formed.
- the lipids are detached from the piston wall by ultrasound treatment (max. 10 min). It is hydrated for 15 min at room temperature (PO PC as carrier lipid) or at 50 ° C (with DMPC, DPPC as carrier lipid).
- the liposome fractions are mixed with the same volume of 2.4 M sucrose in H 2 O (ie a 1.2 M solution is formed).
- the gradient is layered with buffer (10 mM Hepes, 150 mM NaCl, pH 7.5), including 0.8 M sucrose in buffer and below the liposomes in 1.2 M sucrose in H 2 O.
- the volume of the gradient is maximal 4.5 ml.
- the flotation is carried out at room temperature for 45 min at 50,000 rpm in an ultracentrifuge.
- the liposomes, which are located between the 0.8 M sucrose and the buffer layer, are removed.
- the assay is carried out in a final volume of 200 ⁇ l.
- a calibration series of the siRNA is made between 1 ng and 10 ng (10-100 ⁇ l 100 ng / ml siRNA).
- the Ribo Green is diluted 1: 2000 in TE buffer. 100 ⁇ l of Ribo Green are added to each batch, then incubated for 5 min at room temperature and the fluorescence is measured at 485/520 nm.
- the batches are mixed with 4 ⁇ l of 10% Triton (final concentration 0.2 mM). This calibration curve will later be used to determine the amount of siRNA enclosed in liposomes. After about 15 minutes, the fluorescence is measured again.
- the results are entered graphically in a diagram (one curve each with and without Triton) and calibration lines with the corresponding equations are generated from the values.
- the liposomes are diluted in two different concentrations (e.g. 1:50 and 1: 100) and 2-3 different volumes of the dilutions are measured (e.g. 5, 10 and 15 ⁇ l of the dilutions to 100 ⁇ l TE plus 100 ⁇ l Ribo Green reagent ) without and with Triton.
- concentration of the siRNA of a formulation must roughly match in the different measurements. If this is not the case, the siRNA amount was outside the calibration curves and these values should not be included in the calculation of the concentration.
- the efficiency with which the siRNA could be included in various formulations is shown in Table 2.
- Unmodified siRNA is broken down very quickly in the serum.
- the concentration of the included siRNA is determined before the serum test. Liposomes with 4 ⁇ g siRNA per time are used for each time to be tested. Tested times: zero, 1 h, 2 h and 4 h.
- the liposomes with 4 ⁇ g siRNA inside are diluted to a volume of 60 ⁇ l with the buffer in which the liposomes are located (usually 10 mM Hepes, 150 mM NaCl, pH 7.5). 60 ⁇ l of serum are added to the batches and up to the incubated at 37 ° C at appropriate times. The zero time is determined separately.
- a phenol / chloroform extraction is carried out with PLG-Eppis (phase lock gel Eppendor tubes) for a good separation of the serum components and the lipids from the siRNA.
- the PLG-Eppis are centrifuged for 1 min at 13,000 rpm and placed on ice (in the following, work is carried out at max. 4 ° C). 280 ⁇ l of buffer (as above) and 45 ⁇ l of 5 M NaCI are added to the PLG-Eppis.
- the liposomes in the serum (120 ⁇ l) are added to this solution. Immediately afterwards, 300 ⁇ l phenol / chloroform mixture is added. For the zero value, 60 ⁇ l serum is also added to the buffer with NaCI in the PLG-Eppi. Everything is mixed immediately. Centrifugation for 10 min at 13,000 rpm and 4 ° C follows. the aqueous phase contains the free siRNA. A further 300 ⁇ l of chloroform are added to the gradient and mixed briefly. After a further centrifugation as above, the aqueous phase is clear and can be removed as completely as possible. The siRNA is now precipitated from the aqueous phase.
- the quality of the siRNA is checked in the denaturing and possibly also in the native acrylamide gel.
- siRNA The quality of siRNA is determined over the full length of the single strands and the
- Double-strandedness defined. Using a native acrylamide gel, you can
- the gel must be pre-run with TBE buffer for 30 min (80 V, 100 mA) to achieve the required
- a maximum of 2 ⁇ g siRNA per slot should be applied, otherwise the gel will be overloaded.
- the samples are taken up in a total volume of 9 ⁇ l. Then add 1 ⁇ l of Blue Juice loading buffer. The samples are applied to the previous gel and separated for 1 h at 100 mA.
- Staining the gel The gel is removed from the apparatus after electrophoresis. Approx. 200 ml Stains All working solution (20 ml stock solution, 180 ml formamide, 200 ml water) are added to the gel. The gel is stained in the dark for 30-60 min in the Stains All solution. The solution is then removed from the gel and the gel is decolorized under the influence of light in the water (approx. 30 min-2 h depending on the light intensity) . The siRNA remains colored, whereas the background is completely decolored again.
- HepG2 cells are sown in 96-well plates 2 days before the transfection, so that they show a cell density of 60-80% on the day of the transfection (0.02-0.2 x 10 5 in 100 ⁇ l, usually 1 x 10 4 ) , Two plates (centrifugation and control incubation) are prepared, which are otherwise treated identically.
- liposome dilutions with and without cargo
- transfection mix of commercial control transfection reagents (e.g. Lipofectamine 2000, oligofecate mine, siPort amine, siPort lipid) on a 96-well plate with serum-free medium (approx. 160 ng antisense / well).
- the liposome dilution will be added to the cells in a volume of 25-50 ⁇ l.
- the cells are washed with serum-free medium (1x) and mixed with serum-containing or serum-free medium, e.g. 75 ⁇ l per well if the liposome dilutions were prepared in such a way that the corresponding amount of antisense / well is contained in 25 ⁇ l.
- a multiwell plate is centrifuged at 1,500 rpm (342 g), 1 h, 37 ° C., the control plate is incubated for 1 h (37 ° C., 5% CO 2 ). Then both plates are incubated for 3 h (37 ° C, 5% CO 2 ). Remove medium from all wells completely, wash 1 x with PBS, 2 x with serum-containing medium; Add serum-containing medium to all wells, microscopic control for vitality, then incubate both plates overnight (37 ° C, 5% CO 2 ).
- Figure 3 shows a fluorescence image next to a phase contrast image for cell localization.
- Example 7 Determination of the serum stability of amphoteric liposomes with and without cholesterol and / or matrix lipid
- E1 DC-Chol / DOPA (66/34) E2 DC-Chol / DOPA / Chol (40/20/40) E3 DMPC / DC-Chol / DOPA (60/27/13) E4 DMPC / DC-Chol / DOPA / Chol (20/27/13/40) E5 DMPC / DC-Chol / DOPA / Chol (30/20/10/40) E6 DMPC / DC-Chol / DOPA / Chol (40/13/7/40)
- the liposomes were floated after extrusion to separate the outside FITC dextran.
- the following data were measured on the Zetasizer at pH 3.9 (10 mM Hepes 150 NaCI HAc) or pH 9.0 (10 mM Tris 150 mM NaCI):
- ⁇ 1 mM liposomes were incubated for 3 hours at 37 ° C. in human serum and then floated.
- the fluorescence was determined both in the non-floated sample and in the lower layer (serum layer) of the floated sample and the cargo release was calculated therefrom.
- the proportion outside FITC-dextran at the start of the test was determined in the same way by appropriate dilution in buffer pH 3.9 and subsequent flotation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005229485A AU2005229485A1 (en) | 2004-03-28 | 2005-03-29 | Serum-stable amphoteric liposomes |
CA2561247A CA2561247C (en) | 2004-03-28 | 2005-03-29 | Serum-stable amphoteric liposomes |
EP05740433A EP1734928A2 (en) | 2004-03-28 | 2005-03-29 | Serum-stable amphoteric liposomes |
JP2007504251A JP2007530462A (en) | 2004-03-28 | 2005-03-29 | Serum stable amphoteric liposomes |
US10/594,553 US8236770B2 (en) | 2004-03-28 | 2005-03-29 | Serum-stable amphoteric liposomes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004016020.1 | 2004-03-28 | ||
DE200410016020 DE102004016020A1 (en) | 2004-03-28 | 2004-03-28 | Amphoteric liposomal formulations, especially for parenteral applications, contains at least one active substance and neutral lipids as the liposomes with serum stability |
DE102004054730.0 | 2004-11-05 | ||
DE102004054730A DE102004054730A1 (en) | 2004-03-28 | 2004-11-05 | Serum stable amphoteric liposomes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005094783A2 true WO2005094783A2 (en) | 2005-10-13 |
WO2005094783A3 WO2005094783A3 (en) | 2006-03-02 |
Family
ID=34980311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2005/000589 WO2005094783A2 (en) | 2004-03-28 | 2005-03-29 | Serum-stable amphoteric liposomes |
Country Status (7)
Country | Link |
---|---|
US (1) | US8236770B2 (en) |
EP (1) | EP1734928A2 (en) |
JP (1) | JP2007530462A (en) |
AU (1) | AU2005229485A1 (en) |
CA (1) | CA2561247C (en) |
DE (1) | DE102004054730A1 (en) |
WO (1) | WO2005094783A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006048329A1 (en) * | 2004-11-05 | 2006-05-11 | Novosom Ag | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
WO2006053646A2 (en) * | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
EP1764090A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Amphoteric liposomes for local drug applications |
WO2007064857A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
WO2008043575A2 (en) * | 2006-10-13 | 2008-04-17 | Novosom Ag | Improvements in or relating to amphoteric liposomes |
EP1960415A2 (en) * | 2005-11-16 | 2008-08-27 | IDEXX Laboratories Inc | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
EP2004141A2 (en) * | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
WO2009047006A2 (en) * | 2007-10-12 | 2009-04-16 | Novosom Ag | Amphoteric liposomes comprising neutral lipids |
EP2141173A1 (en) * | 2004-06-01 | 2010-01-06 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
WO2014071406A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
EP3000480A1 (en) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
WO2016125163A1 (en) | 2015-02-04 | 2016-08-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815599B2 (en) * | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
GB0720486D0 (en) * | 2007-10-19 | 2007-11-28 | Univ Edinburgh | Cationic lipids |
EP2306978A2 (en) * | 2008-06-06 | 2011-04-13 | Mirna Therapeutics, Inc. | Compositions for the in vivo delivery of rnai agents |
JP5836394B2 (en) * | 2010-12-30 | 2015-12-24 | サムヤン バイオファーマシューティカルズ コーポレイション | Anionic drug carrier containing cationic lipid and method for producing the same |
US11633365B2 (en) | 2017-08-04 | 2023-04-25 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066012A2 (en) * | 2001-02-21 | 2002-08-29 | Novosom Ag | Amphoteric liposomes and the use thereof |
WO2003070735A2 (en) * | 2002-02-19 | 2003-08-28 | Novosom Ag | Components for producing amphoteric liposomes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6649780B1 (en) * | 1998-12-22 | 2003-11-18 | Valentis, Inc. | Cationic lipids |
CA2587337A1 (en) * | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
-
2004
- 2004-11-05 DE DE102004054730A patent/DE102004054730A1/en not_active Ceased
-
2005
- 2005-03-29 EP EP05740433A patent/EP1734928A2/en not_active Withdrawn
- 2005-03-29 AU AU2005229485A patent/AU2005229485A1/en not_active Abandoned
- 2005-03-29 US US10/594,553 patent/US8236770B2/en not_active Expired - Fee Related
- 2005-03-29 CA CA2561247A patent/CA2561247C/en not_active Expired - Fee Related
- 2005-03-29 JP JP2007504251A patent/JP2007530462A/en active Pending
- 2005-03-29 WO PCT/DE2005/000589 patent/WO2005094783A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066012A2 (en) * | 2001-02-21 | 2002-08-29 | Novosom Ag | Amphoteric liposomes and the use thereof |
WO2003070735A2 (en) * | 2002-02-19 | 2003-08-28 | Novosom Ag | Components for producing amphoteric liposomes |
Non-Patent Citations (3)
Title |
---|
BUDKER V ET AL: "PH-SENSITIVE, CATIONIC LIPOSOMES: A NEW SYNTHETIC VIRUS-LIKE VECTOR" BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, Bd. 14, Juni 1996 (1996-06), Seiten 760-764, XP002937150 ISSN: 0733-222X * |
LEVENTIS R ET AL: "ph-dependent stability and fusion of liposomes combining protonatable double-chain amphiphiles with phosphatidylethanolamine" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, Bd. 26, Nr. 12, 1987, Seiten 3267-3276, XP002025621 ISSN: 0006-2960 * |
LI X-J ET AL: "THEORY OF TUNABLE PH-SENSITIVE VESICLES OF ANIONIC AND CATIONIC LIPIDS OR ANIONIC AND NEUTRAL LIPIDS" BIOPHYSICAL JOURNAL, NEW YORK, US, US, Bd. 80, Nr. 1, PART 2, April 2001 (2001-04), Seiten 1703-1711, XP008005325 ISSN: 0006-3495 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2141173A1 (en) * | 2004-06-01 | 2010-01-06 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
EP1658839A1 (en) * | 2004-11-05 | 2006-05-24 | Novosom AG | Oligonucleotide/carrier combinations targeting CD40 |
WO2006048329A1 (en) * | 2004-11-05 | 2006-05-11 | Novosom Ag | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
WO2006053646A2 (en) * | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
WO2006053646A3 (en) * | 2004-11-19 | 2006-08-17 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
EP1764090A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Amphoteric liposomes for local drug applications |
EP1960415A2 (en) * | 2005-11-16 | 2008-08-27 | IDEXX Laboratories Inc | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
EP1960415A4 (en) * | 2005-11-16 | 2011-09-21 | Idexx Lab Inc | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
WO2007064857A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
WO2007064857A3 (en) * | 2005-12-01 | 2007-08-30 | Pronai Therapeutics Inc | Amphoteric liposome formulation |
EP3000480A1 (en) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
EP2004141A2 (en) * | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
JP2010505899A (en) * | 2006-10-13 | 2010-02-25 | ノヴォソム アクチェンゲゼルシャフト | Improvements in or on amphoteric liposomes, methods of formulating amphoteric liposomes and methods of filling amphoteric liposomes |
AU2007306556B2 (en) * | 2006-10-13 | 2014-04-10 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
AU2014203387B2 (en) * | 2006-10-13 | 2016-07-07 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
WO2008043575A2 (en) * | 2006-10-13 | 2008-04-17 | Novosom Ag | Improvements in or relating to amphoteric liposomes |
WO2008043575A3 (en) * | 2006-10-13 | 2008-09-04 | Novosom Ag | Improvements in or relating to amphoteric liposomes |
US9283186B2 (en) | 2006-10-13 | 2016-03-15 | Marina Biotech, Inc. | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
EP2462924A3 (en) * | 2006-10-13 | 2013-01-23 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes. |
WO2009047006A3 (en) * | 2007-10-12 | 2009-09-24 | Novosom Ag | Amphoteric liposomes comprising neutral lipids |
AU2008309880B2 (en) * | 2007-10-12 | 2014-07-10 | Biontech Delivery Technologies Gmbh | Amphoteric liposomes comprising neutral lipids |
JP2015110625A (en) * | 2007-10-12 | 2015-06-18 | マリーナ バイオテック,インコーポレイテッド | Amphoteric liposome comprising neutral lipid |
JP2011500520A (en) * | 2007-10-12 | 2011-01-06 | ノヴォソム アクチェンゲゼルシャフト | Improvement of amphoteric liposomes containing neutral lipids or improvements related to the amphoteric liposomes |
WO2009047006A2 (en) * | 2007-10-12 | 2009-04-16 | Novosom Ag | Amphoteric liposomes comprising neutral lipids |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
WO2014071406A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
WO2016125163A1 (en) | 2015-02-04 | 2016-08-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES |
US10722599B2 (en) | 2015-02-04 | 2020-07-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies |
Also Published As
Publication number | Publication date |
---|---|
CA2561247A1 (en) | 2005-10-13 |
AU2005229485A1 (en) | 2005-10-13 |
DE102004054730A1 (en) | 2006-05-11 |
AU2005229485A2 (en) | 2005-10-13 |
CA2561247C (en) | 2014-12-09 |
JP2007530462A (en) | 2007-11-01 |
EP1734928A2 (en) | 2006-12-27 |
US8236770B2 (en) | 2012-08-07 |
WO2005094783A3 (en) | 2006-03-02 |
US20080311181A1 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005094783A2 (en) | Serum-stable amphoteric liposomes | |
DE69906977T2 (en) | NUCLEIC ACID COMPLEXES ENCLOSED IN LIPOSOMES | |
DE60017406T2 (en) | PROCESS FOR PREPARING LIPID-CAPTAIDED THERAPEUTIC AGENTS | |
EP1838286B1 (en) | Production of lipid-based nanoparticles using a dual asymmetrical centrifuge | |
EP1363932B1 (en) | Amphoteric sterols and the use thereof | |
DE69633669T2 (en) | METHOD FOR CELL TRANSFECTION WITH LIPOSOMAL-SECRETED NUCLEIC ACIDS | |
DE60036861T2 (en) | Encapsulation of biologically active complexes in liposomes | |
EP1289642B2 (en) | Nanocapsules having a polyelectrolyte envelope | |
KR101085203B1 (en) | Phospholipid nanoparticles for delivery of drugs | |
EP1764089A1 (en) | Serum stable liposomes comprising amphoter II lipid mixtures | |
EP1512393A1 (en) | Process for the production of homogeneous liposomes and lipoplexes | |
DE102009032658A1 (en) | Mixture of amphipathic molecules and methods of cell membrane modification by fusion | |
KR20200084338A (en) | Fusable compounds for delivery of biologically active molecules | |
DE4430592A1 (en) | Liposomal preparation, its preparation and its use | |
DE3416978A1 (en) | TRANSFORMATION OF EUKARYOTIC CELLS MEDIATED BY LIPOSOME | |
EP1628636A1 (en) | Injectable liposomal depots for delivering active ingredients | |
WO1997031927A1 (en) | Tetraether lipids and liposomes containing said lipids, and use of the same | |
WO2014154203A2 (en) | Fusion mixture | |
DE60132670T2 (en) | OLIGONUCLEOTIDE SUPPORTED COALESCENCE | |
DE102004016020A1 (en) | Amphoteric liposomal formulations, especially for parenteral applications, contains at least one active substance and neutral lipids as the liposomes with serum stability | |
DE19736592C2 (en) | Tetraether lipid derivative, one or more tetraether lipid derivatives containing liposome or lipid agglomerate and pharmaceutical composition | |
DE3610873A1 (en) | PHOSPHOLIPID VESICLE AND METHOD FOR THE PRODUCTION THEREOF | |
DE10361917A1 (en) | In vitro transfection of cells, useful e.g. in animal tests and for human applications, comprises centrifuging the cells with active agents, preferably packaged in liposomes | |
DE19925143A1 (en) | New liposomal vector complexes and their use for gene therapy | |
DE102006054192A1 (en) | Method for loading nucleic acid active substances within amphoteric liposomes, comprises: mixing lipid mixture solution and aqueous solution of nucleic acid active substances; and sterile filtrating the liposomes containing the substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2561247 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007504251 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5781/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005229485 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005740433 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005229485 Country of ref document: AU Date of ref document: 20050329 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005229485 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005740433 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10594553 Country of ref document: US |